Europe’s medical devices industry saw a rise of 31.58% in cross border deal activity during November 2021, when compared with the last 12-month average, led by Coloplast’s $2.49bn acquisition of Atos Medical, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 25 medical devices industry cross border deals worth $2.7bn were announced for the region in November 2021, against the 12-month average of 19 deals.
Of all the deal types, M&A saw most activity in November 2021 with 14 transactions, representing a 56% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was venture financing with eight deals, followed by private equity deals with three transactions, respectively capturing a 32% and 12% share of the overall cross border deal activity for the month.
In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.55bn, while venture financing and private equity deals totalled $114.74m and $12.73m, respectively.
Europe medical devices industry cross border deals in November 2021: Top deals
The top five medical devices cross border deals accounted for 97.8% of the overall value during November 2021.
The combined value of the top five medical devices cross border deals stood at $2.61bn, against the overall value of $2.7bn recorded for the month.
The top five medical devices industry cross border deals of November 2021 tracked by GlobalData were:
1) Coloplast $2.49bn acquisition deal with Atos Medical
2) The $49.52m acquisition of 17.8% stake in InnovHeart by Grand Pharmaceutical Group
3) Horizon Ventures and Sofinnova Partners $35m venture financing deal with Synthace
4) The $20.24m venture financing of QuantuMDx Group by Vita Spring IVD Fund
5) 415 Capital Management,Draper Esprit,Redalpine Venture Partners,Translink Capital and Verve Capital Partners $17.5m venture financing deal with Aktiia
